Comparative Study of Ologen Collagen Matrix Versus Mitomycin-C in Trabeculectomy: A Study in Germany
Launched by AEON ASTRON EUROPE B.V. · Aug 2, 2010
Trial Information
Current as of August 11, 2025
Unknown status
Keywords
ClinConnect Summary
ologen® Collagen Matrix (CM) is an artificial extracellular matrix (ECM) specifically configured to support repair in connective and epithelial ocular tissue. The device is constructed so as to minimize random growth of fibroblasts and instead to allow them to grow through the pores in the matrix. ologen® CM is a biodegradable scaffold matrix, inducing a regenerative non-scarring wound healing process without using anti-fibrotic agents. For application in glaucoma filtration surgery, ologen® CM is designed to prevent scar formation (subconjunctival and scleral flap scarring is the major ris...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 years or over
- • Uncontrolled open-angle glaucoma
- • Subject is willing to sign informed consent
- • Subject is able and willing to complete post-operative follow-up requirements
- Exclusion Criteria:
- • Inflammatory eye diseases
- • Angle-closure glaucoma
- • Secondary glaucoma with anatomical malformations of the eye
- • Subjects having single functional eye
- • Previous conjunctival surgery
- • Known allergic reactions to ingredients of ologen Collagen Matrix
- • Excessive myopia (axial length (AL)\> 27 mm or more than -10 diopters)
- • Previous vitrectomy eye surgery
- • Subjects do not consent to participate
About Aeon Astron Europe B.V.
Aeon Astron Europe B.V. is a leading clinical trial sponsor dedicated to advancing healthcare through innovative research and development. Based in Europe, the company specializes in the development of novel therapeutics and diagnostics across various therapeutic areas. With a commitment to rigorous scientific standards and patient safety, Aeon Astron collaborates with healthcare professionals and institutions to conduct high-quality clinical trials that aim to bring cutting-edge treatments to market. Their expertise in regulatory compliance and trial management positions them as a trusted partner in the global clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cologne, , Germany
Patients applied
Trial Officials
Thomas Dietlein, MD
Principal Investigator
Department of Ophthalmology, University of Cologne, Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials